BACKGROUND: Irreversible electroporation (IRE) has emerged as a novel, safe ablative therapy for peri-vascular lesions. However, there remains a paucity of data on long-term outcomes. METHODS: We identified patients who underwent open IRE (1/2011-6/2015) for primary and secondary hepatic malignancies. Local ablation-zone recurrence (LR) was determined by cross-sectional imaging. Cumulative incidence (CumI) of LR was calculated and a competing risks regression assessed factors associated with LR. RESULTS: Forty patients had 77 lesions treated. The majority of lesions were of colorectal origin (74%). Median tumor size was 1.3 cm (range 0.5-6). Most patients (86%) had prior systemic therapy and 29% received systemic therapy following IRE. With a median follow-up of 25.7 months (range 4.5-58.8 months), 10 lesions in 9 patients recurred locally (CumI: 13.4%, 95%CI: 7.8-22.2%). Median estimated time to LR was not reached and no LR occurred after 19 months. Factors significantly associated with LR included ablation zone size (HR 1.58; 95%CI 1.12-2.23; P = 0.0093) and body mass index (HR 1.21 95%CI 1.10-1.34; P = 0.0001). CONCLUSION: IRE LR rates were low after the treatment of well selected, small tumors. This technique is useful for lesions in anatomic locations precluding resection or thermal ablation.
BACKGROUND: Irreversible electroporation (IRE) has emerged as a novel, safe ablative therapy for peri-vascular lesions. However, there remains a paucity of data on long-term outcomes. METHODS: We identified patients who underwent open IRE (1/2011-6/2015) for primary and secondary hepatic malignancies. Local ablation-zone recurrence (LR) was determined by cross-sectional imaging. Cumulative incidence (CumI) of LR was calculated and a competing risks regression assessed factors associated with LR. RESULTS: Forty patients had 77 lesions treated. The majority of lesions were of colorectal origin (74%). Median tumor size was 1.3 cm (range 0.5-6). Most patients (86%) had prior systemic therapy and 29% received systemic therapy following IRE. With a median follow-up of 25.7 months (range 4.5-58.8 months), 10 lesions in 9 patients recurred locally (CumI: 13.4%, 95%CI: 7.8-22.2%). Median estimated time to LR was not reached and no LR occurred after 19 months. Factors significantly associated with LR included ablation zone size (HR 1.58; 95%CI 1.12-2.23; P = 0.0093) and body mass index (HR 1.21 95%CI 1.10-1.34; P = 0.0001). CONCLUSION: IRE LR rates were low after the treatment of well selected, small tumors. This technique is useful for lesions in anatomic locations precluding resection or thermal ablation.
Authors: T Peter Kingham; Ami M Karkar; Michael I D'Angelica; Peter J Allen; Ronald P Dematteo; George I Getrajdman; Constantinos T Sofocleous; Stephen B Solomon; William R Jarnagin; Yuman Fong Journal: J Am Coll Surg Date: 2012-06-16 Impact factor: 6.113
Authors: H J Scheffer; K Nielsen; A A J M van Tilborg; J M Vieveen; R A Bouwman; G Kazemier; H W M Niessen; S Meijer; C van Kuijk; M P van den Tol; M R Meijerink Journal: Eur Radiol Date: 2014-06-18 Impact factor: 5.315
Authors: Thomas J Vogl; Parviz Farshid; Nagy N N Naguib; Abbas Darvishi; Babak Bazrafshan; Emmanuel Mbalisike; Thorsten Burkhard; Stephan Zangos Journal: Radiol Med Date: 2014-06-04 Impact factor: 3.469
Authors: Mikhail T Silk; Thomas Wimmer; Kyungmouk S Lee; Govindarajan Srimathveeravalli; Karren T Brown; Peter T Kingham; Yuman Fong; Jeremy C Durack; Constantinos T Sofocleous; Stephen B Solomon Journal: J Vasc Interv Radiol Date: 2013-11-18 Impact factor: 3.464
Authors: Fourat Ridouani; Mario Ghosn; Francois Cornelis; Elena N Petre; Meier Hsu; Chaya S Moskowitz; Peter T Kingham; Stephen B Solomon; Govindarajan Srimathveeravalli Journal: Medicina (Kaunas) Date: 2021-08-26 Impact factor: 2.948
Authors: Chelsea M Edelblute; James Hornef; Niculina I Burcus; Thomas Norman; Stephen J Beebe; Karl Schoenbach; Richard Heller; Chunqi Jiang; Siqi Guo Journal: Sci Rep Date: 2017-09-18 Impact factor: 4.379
Authors: Chelsea M Edelblute; Siqi Guo; James Hornef; Enbo Yang; Chunqi Jiang; Karl Schoenbach; Richard Heller Journal: Technol Cancer Res Treat Date: 2018-01-01
Authors: Wolf Bäumler; Philipp Wiggermann; Lukas Lürken; Marco Dollinger; Christian Stroszczynski; Lukas P Beyer; Andreas Schicho Journal: Cancers (Basel) Date: 2021-03-30 Impact factor: 6.639